Navigation Links
ThromboGenics NV Announces Business Update and Half Year Results 2009
Date:8/27/2009

LEUVEN, Belgium, August 27 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its half year results for the six month period ending 30 June, 2009.

During 2009, ThromboGenics has continued to focus on the activities which are key to its aim of becoming a profitable, integrated company focused on cutting edge ophthalmic medicines. Central to this plan is the Company's lead product, microplasmin, which is in Phase III trials for the treatment of back of the eye disease. Patient recruitment in this Phase III program is running smoothly and the Company expects to report the first results from these studies by mid 2010.

The clinical development of the Company's unique long-acting anticoagulant TB-402, which is in Phase II trials for the prevention of deep vein thrombosis (DVT) following orthopaedic surgery, has progressed more rapidly than originally expected.

Patrik De Haes, CEO of ThromboGenics, said:

"ThromboGenics has seen most of its key programs make significant progress during the course of 2009. We are very happy with the speed of patient recruitment in the microplasmin Phase III program. Microplasmin is central to our aim of building a strong, profitable and integrated company centered on cutting edge ophthalmic medicines. Given our increasing confidence in the clinical merits of microplasmin we are now starting to develop our commercialization plans for this novel product. We are also very encouraged by the progress of the Phase II program for TB-402, as recruitment is ahead of schedule. This clinical study has reinforced our view that we have an attractive out-licensing opportunity for companies keen to enhance their position in the anti-coagulant therapy market. Our partnership with
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... . , Electrical ... a new kind of building block for digital integrated ... be based on three-dimensional arrangements of nanometer-scale magnets instead ... semiconductor industry CMOS fabrication of silicon chips ... the University of Notre Dame are exploring "magnetic computing" ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Shimadzu ... extensometer, an easy-to-use and highly precise tool for ... with considerable elongation. With 1000-mm maximum movement distance, ... percent for a gauge length of 10 mm. ... measurement accuracy above 50-mm stroke and within +/- ...
(Date:9/30/2014)... September 30, 2014 Follow us ... of each type of cholesterol carrier or lipoprotein in ... of excessive cholesterol levels in the body, especially along ... to heart attack and other cardiovascular disorders. Cardiovascular Diseases ... testing for cholesterol levels on a regular basis, to ...
(Date:9/30/2014)... 30, 2014 Genedata, a ... drug discovery and related life science research, ... chosen Genedata Selector as its host-pathogen data ... FUNGITECT is a European consortium dedicated to ... via individualized anti-fungal drug therapies. Genedata Selector ...
Breaking Biology Technology:A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3
... , , , Genetic reporter ... regulatory promoter and enhancer sequences as well as transcription factors. , ... enhancer) is cloned , together with the reporter ... used to transfect cells. Quantification of the reporter indirectly provides , ...
... , , , , Using eukaryotic ... to a hypoosmolar buffer system and short pulses in the s-range. , ... of sample resistance (patent pending)., , , ... Two cell lines (mouse fibroblast cells, human T-lymphocytes) were transfected ...
... , , , , , , PLG can be used ... The basic protocol given here works with E. coli cultures grown for 1214 , ... , ml Terrific Broth. , , ... 10,000 x g for 5 minutes at room , temperature. ...
Cached Biology Technology:Genetic Reporter Systems 2Genetic Reporter Systems 3Genetic Reporter Systems 4Basic Plasmid DNA Isolation Protocol 2
(Date:10/1/2014)... October 1, 2014 ... der Biowissenschaften   Die Biowissenschaften erlebten ... Gehen zahlreicher Detektionstechnologien. Einige davon sind Senkrechtstarter ... Die Photonen-Upconversion ist eine neuartige Detektionstechnologie, die ... Begeisterung aufgenommen wurde. Jetzt ist diese Technologie ...
(Date:9/30/2014)... visit the Mediterranean each year, but its deep-blue ... Earth. Almost 1,000 alien species, including fish, crustaceans, ... through human activities. In the open-access journal ... of researchers analyzed data from a new information ... how the introduction of alien species has changed ...
(Date:9/30/2014)... as something that we enjoy when we visit a national ... think of ourselves as a part of nature? A bird,s ... house? , The answers to these questions reflect different ... speech and in cultural artifacts. , A new Northwestern University ... Indian Center of Chicago and the Menominee tribe of Wisconsin, ...
Breaking Biology News(10 mins):Innovative Verwendungslösung für die Photonen-Upconversion 2Innovative Verwendungslösung für die Photonen-Upconversion 3Biodiversity in the Mediterranean is threatened by alien species 2The cultural side of science communication 2
... University professor of physics and astronomy Apparao Rao has ... Fellows are elected by their peers for outstanding contributions ... one half of 1 percent of the membership. ... nanotubes and for elucidating the properties of carbon nanotubes ...
... PITTSBURGHUniversity of Pittsburgh researchers have developed the first ... finding that could help diminish the environmental and ... of the super-strong materials commonly used in products, ... team has found that carbon nanotubes deteriorate when ...
... 16, 2008) Researchers from Virginia Commonwealth University have identified ... and suppress a key protein that is overexpressed in 90 ... to an effective gene therapy for cancer. According ... the Department of Human and Molecular Genetics and director of ...
Cached Biology News:Pitt researchers create non-toxic clean-up method for potentially toxic nano materials 2Researchers identify new anti-tumor gene 2
... Microplate Rack inserts fit into ... and allow you to greatly ... shake deepwell format plates at ... plates from the shaker at ...
BD FastImmune EDTA Solution. Applications: Flow Cytometry Storage Temperature: Refrigerate(2 to 8C)...
Spaced cover glasses to promote effective hybridization...
prototype Nco I...
Biology Products: